Jennifer M. Giltnane, M.D., Ph.D
Instructor in Pathology, Microbiology and Immunology
Patient Contact Information:
Healthcare Provider Contact Information:
2220 Pierce Avenue
649 Preston Research Building
Nashville, TN 37232
Dr. Giltnane is a junior faculty breast pathologist with a special interest in diagnostic quality improvement for the management and treatment of breast disease. She has research expertise in the development genomic and proteomic biomarkers for diagnosis, prediction, and prognosis in breast cancer as well as clinical expertise in the processing of tissue specimens and biobanking. She is currently supported by the Department of Pathology, Microbiology, and Immunology to pursue post-doctoral training in the laboratory of Carlos Artega, M.D., focused on translational research technologies including next-generation sequencing toward the improvement of outcomes in breast cancer.
Predictive biomarker discovery and validation for translational oncology research
I am continuing my career at Vanderbilt with a focus on biomarker discovery and validation for the prediction of treatment resistance and recurrence in breast cancer. Currently, I am exploring the mechanisms of resistance to endocrine therapy, utilizing the accrued tissue in the BRE0776 presurgical letrozole trial as part of the VICC's Breast SPORE. Through multi-platform molecular profiling of these tumors, I hope to identify actionable somatic alterations and uncover additional therapeutic liabilities to overcome endocrine resistance in early breast cancer. A long-term goal is to develop a cost-effective, protein-based biomarker assay to predict endocrine-response in ER+ breast cancer, informed by my experience with quantitative protein measurements in tissue.
Biobanking and tissue management for clinical studies, tissue microarray studies of clinical trial cohorts
- Chmielecki, J, Peifer, M, Viale, A, Hutchinson, K, Giltnane, J, Socci, ND, Hollis, CJ, Dean, RS, Yenamandra, A, Jagasia, M, Kim, AS, DavÃ©, UP, Thomas, RK, Pao, W Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer, 51(1), 54-65, 2012.
- Anagnostou, VK, Welsh, AW, Giltnane, JM, Siddiqui, S, Liceaga, C, Gustavson, M, Syrigos, KN, Reiter, JL, Rimm, DL Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev, 19(4), 982-91, 2010.
- Rokicki, J, Das, PM, Giltnane, JM, Wansbury, O, Rimm, DL, Howard, BA, Jones, FE The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer, 9150, 2010.
- Giltnane, JM, Moeder, CB, Camp, RL, Rimm, DL Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer, 115(11), 2400-9, 2009.
- Moeder, CB, Giltnane, JM, Moulis, SP, Rimm, DL Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol, 520163-75, 2009.
- Giltnane, JM, Molinaro, A, Cheng, H, Robinson, A, Turbin, D, Gelmon, K, Huntsman, D, Rimm, DL Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med, 132(10), 1635-47, 2008.
- Nadler, Y, Camp, RL, Giltnane, JM, Moeder, C, Rimm, DL, Kluger, HM, Kluger, Y Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res, 10(2), R35, 2008.
- Rimm, DL, Giltnane, JM, Moeder, C, Harigopal, M, Chung, GG, Camp, RL, Burtness, B Bimodal population or pathologist artifact (Letter to the editor). J Clin Oncol, 25(17), 2487-8, 2007.
- Pick, E, Kluger, Y, Giltnane, JM, Moeder, C, Camp, RL, Rimm, DL, Kluger, HM High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res, 67(7), 2932-7, 2007.
- *Moeder, CB, *Giltnane, JM, Harigopal, M, Molinaro, A, Robinson, A, Gelmon, K, Huntsman, D, Camp, RL, Rimm, DL. *Authors contributed equally Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol, 25(34), 5418-25, 2007.
- Giltnane, JM, RydÃ©n, L, Cregger, M, Bendahl, PO, JirstrÃ¶m, K, Rimm, DL Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol, 25(21), 3007-14, 2007.
- Giltnane, JM, Murren, JR, Rimm, DL, King, BL AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology, 49(2), 161-9, 2006.
- Dolled-Filhart, M, McCabe, A, Giltnane, J, Cregger, M, Camp, RL, Rimm, DL Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res, 66(10), 5487-94, 2006.
- Cahir-McFarland, ED, Carter, K, Rosenwald, A, Giltnane, JM, Henrickson, SE, Staudt, LM, Kieff, E Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol, 78(8), 4108-19, 2004.
- Giltnane, JM, Rimm, DL Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol, 1(2), 104-11, 2004.
- Kovanen, PE, Rosenwald, A, Fu, J, Hurt, EM, Lam, LT, Giltnane, JM, Wright, G, Staudt, LM, Leonard, WJ Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J Biol Chem, 278(7), 5205-13, 2003.
- McConnell, MJ, Chevallier, N, Berkofsky-Fessler, W, Giltnane, JM, Malani, RB, Staudt, LM, Licht, JD Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol, 23(24), 9375-88, 2003.
- Rosenwald, A, Wright, G, Wiestner, A, Chan, WC, Connors, JM, Campo, E, Gascoyne, RD, Grogan, TM, Muller-Hermelink, HK, Smeland, EB, Chiorazzi, M, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Henrickson, S, Yang, L, Powell, J, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Montserrat, E, Bosch, F, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Fisher, RI, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Holte, H, Delabie, J, Staudt, LM The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3(2), 185-97, 2003.
- Shaffer, AL, Lin, KI, Kuo, TC, Yu, X, Hurt, EM, Rosenwald, A, Giltnane, JM, Yang, L, Zhao, H, Calame, K, Staudt, LM Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity, 17(1), 51-62, 2002.
- Rosenwald, A, Wright, G, Chan, WC, Connors, JM, Campo, E, Fisher, RI, Gascoyne, RD, Muller-Hermelink, HK, Smeland, EB, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Yang, L, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Powell, J, Duffey, PL, Longo, DL, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Montserrat, E, LÃ³pez-Guillermo, A, Grogan, TM, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Delabie, J, Holte, H, Krajci, P, Stokke, T, Staudt, LM, , The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346(25), 1937-47, 2002.
- MD, Yale University School of Medicine, 2008
- PhD, Yale University Graduate School of Arts & Sciences (Experimental Pathology), 2008
- Residency, Anatomic and Clinical Pathology, Vanderbilt University Medical Center, 2012